28 March 2019 | News
This includes three new projects and seven that will receive continued funding.
image credit- asianscientist.com
The Global Health Innovative Technology (GHIT) Fund has announced a total of 2.86 billion yen to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and schistosomiasis. This includes three new projects and seven that will receive continued funding.
Projects & Investments-
Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation- ¥452,329,597
Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes- ¥489,273,750
Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity- ¥536,822,427
Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria- ¥421,418,717
Live attenuated prophylactic vaccine for leishmaniasis- ¥399,898,983
Mitsubishi Tanabe Lead Optimization of Anti-Malarials- ¥192,247,534
New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda- ¥52,800,000
Hit-to-Lead Development of Novel anti-TB Natural Products- ¥119,244,000
Further development of a new asexual blood-stage malaria vaccine candidate- ¥93,057,133
Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria- ¥100,000,000